Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Depreciation and Depletion (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Depreciation and Depletion for 5 consecutive years, with $200000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion fell 6.54% year-over-year to $200000.0, compared with a TTM value of $900000.0 through Dec 2025, down 17.88%, and an annual FY2025 reading of $900000.0, down 10.0% over the prior year.
  • Depreciation and Depletion was $200000.0 for Q4 2025 at Aligos Therapeutics, down from $247000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $800000.0 in Q2 2021 and bottomed at $194000.0 in Q1 2025.
  • Average Depreciation and Depletion over 5 years is $441250.0, with a median of $381500.0 recorded in 2023.
  • Peak annual rise in Depreciation and Depletion hit 0.0% in 2024, while the deepest fall reached 40.39% in 2024.
  • Year by year, Depreciation and Depletion stood at $709000.0 in 2021, then fell by 27.22% to $516000.0 in 2022, then plummeted by 30.43% to $359000.0 in 2023, then plummeted by 40.39% to $214000.0 in 2024, then dropped by 6.54% to $200000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for ALGS at $200000.0 in Q4 2025, $247000.0 in Q3 2025, and $259000.0 in Q2 2025.